Get started
Author

Gülseren Güzel

ORCID: 0009-0002-3081-5107
Observed ORCID: 0009-0002-3081-5107
OpenAlex ID: A5112465432
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
2020 · Sandra P D'Angelo, Shailender Bhatia, et al. · Journal for ImmunoTherapy of Cancer · 203
PDF
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
2021 · Sandra P D'Angelo, Celeste Lebbé, et al. · Journal for ImmunoTherapy of Cancer · 146
PDF
Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial
2020 · Jérémy Lambert, Alexia Marrel, et al. · Patient · 17
PDF
Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma
2024 · Sandra P. D’Angelo, Céleste Lebbé, et al. · Clinical Cancer Research · 11
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
2020 · Murtuza Bharmal, Sandra Nolte, et al. · Future Oncology · 8
PDF
604 First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial
2022 · Sandra D'Angelo, Celeste Lebbé, et al. · Regular and Young Investigator Award Abstracts · 4
PDF
Evaluation of the potential for QTc prolongation with avelumab
2019 · Yulia Vugmeyster, Gülseren Güzel, et al. · Cancer Chemotherapy and Pharmacology · 3
PDF
Correction: A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
2020 · Janice M Mehnert, Isaac Brownell, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Data from Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma
2024 · Sandra P. D’Angelo, Céleste Lebbé, et al.
Supplementary Data 1 from Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma
2024 · Sandra P. D’Angelo, Céleste Lebbé, et al.
Expressionsanalyse humaner Fibrochondrozyten in Zellkultur
2009 · Gülseren Güzel
Works count: 11
Citation count: 392
H-index: 5
I10-index: 4
Year
Topic
Type